An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

NCT05815004 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Further development of programs halted

Conditions

Gaucher Disease, Type 3

Interventions

DRUG: Gene therapy
DRUG: Enzyme Replacement Agent

Sponsor

AVROBIO